107749-65-5

Upstream product

• 142929-53-1 ethyl α-<(phenylmethoxy)methyl>benzenepropanoate 
• 2021-28-5 ethyl dihydrocinnamate 
• 607-81-8 diethyl 2-benzylmalonate 
• 98516-80-4 ethyl 2-formyl-3-phenylpropionate 
• 10029-04-6 ethyl 2-(hydroxymethyl)acrylate 

Downstream Products

• 1198470-65-3 rac-2-benzyl-3-(4-fluoro-benzylamino)-propionic acid ethyl ester 
• 98516-80-4 ethyl 2-formyl-3-phenylpropionate 
• 142929-42-8 methyl 13α-<<2(S)-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropyl>amino>-3,3,14,14-tetramethyl-6,12-dioxo-7-(phenylmethyl)-1,2-dithia-5,11-diazacyclotetradec-8-ene-(4R)-4α-carboxylate hydrochloride 
• 142929-59-7 methyl 13α-<<(1,1-dimethylethoxy)carbonyl>amino>-3,3-14,14-tetramethyl-6,12-dioxo-7-(phenylmethyl)-1,2-dithia-5,11-diazacyclotetradec-8-ene-(4R)-4α-carboxylate 
• 142929-56-4 trichloro-N-<4-(phenylmethyl)-5-<(tetrahydro-2H-pyran-2-yl)oxy>-2(E)-pentenyl>acetamide 
• 142929-58-6 1,1-dimethylethyl <4-(phenylmethyl)-5-<(tetrahydro-2H-pyran-2-yl)oxy>-2(E)-pentenyl>carbamate 
• 142929-55-3 α-ethenyl-β-<<(tetrahydro-2H-pyran-2-yl)oxy>methyl>benzenepropanol 
• 142929-57-5 4-(phenylmethyl)-5-<(tetrahydro-2H-pyran-2-yl)oxy>-2(E)-pentenamine 
• 108385-58-6 3-Phenyl-2-(tetrahydro-pyran-2-yloxymethyl)-propionaldehyde 
• 134161-23-2 α-<3<<(1,1-dimethylethoxy)carbonyl>amino>-1(E)-propenyl>benzenepropanoic acid 
• 142929-54-2 ethyl α-<<(tetrahydro-2H-pyran-2-yl)oxy>methyl>benzenepropanoate 

Relevant academic research and scientific papers

ESTERS α-METHYLENIQUES ET α-HYDROXYMETHYLES PAR ADDITION D'ORGANOLITHIENS OU MAGNESIENS SUR L' α-(HYDROXYMETHYL) ACRYLATE D'ETHYLE ET SES DERIVES EN PRESENCE DE CUIVRE(I)

α-(Methylene)- and α-(hydroxymethyl)-alkanoic esters are prepared by substitution of α-(acetoxymethyl) acrylate by Grignard reagents in the presence of a catalytic amount of copper(I) salt, or by addition of an excess (2.5 equivalents) of dialkylcopper ma

[1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS

The invention is directed to [1,2,4]thiadiazine 1,1-dioxide compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.

PROCESS FOR PRODUCING OPTICALLY ACTIVE 3-HYDROXYPROPIONIC ESTER DERIVATIVE

The present invention is to provide a process for simply producing an optically active 3-hydroxypropionic ester derivative useful as a medicament intermediate from an inexpensive material. More specifically, the present invention is directed to a process for producing an optically active 3-hydroxypropionic ester derivative comprising reacting an acetic ester derivative available at low cost with a base and a formic ester, thereby converting the acetic ester derivative into a 2-formylacetic ester derivative, and thereafter, stereospecifically reducing the formyl group of the derivative by use of an enzymatic source capable of stereoselectively reducing the formyl group of the derivative.

Analogs of the δ opioid receptor selective cyclic peptide [2-D- penicillamine,5-D-penicillamine]-enkephalin: 2',6'-Dimethyltyrosine and Gly3-Phe4 amide bond isostere substitutions

In order to develop systemically-active opioid peptides, the δ-selective, opioid pentapeptide [D-Pen2,D-Pen5]-enkephalin (DPDPE) was modified by esterification and by substitution of 2',6'-dimethyltyrosine for tyrosine to yield 4. Co